Heron Therapeutics Inc [NASDAQ: HRTX] traded at a high on Tuesday, posting a 13.62 gain after which it closed the day’ session at $2.42.
The results of the trading session contributed to over 7414634 shares changing hands. Over the past one week, the price volatility of Heron Therapeutics Inc stands at 10.24% while the volatility over the past one month is 8.38%.
The market cap for HRTX stock reached $368.64 million, with 152.13 million shares outstanding and 150.92 million shares in the current float. Compared to the average trading volume of 1.78M shares, HRTX reached a trading volume of 7414634 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Heron Therapeutics Inc [HRTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for HRTX shares is $6.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on HRTX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Rodman & Renshaw have made an estimate for Heron Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 13, 2024. While these analysts kept the previous recommendation, CapitalOne raised their target price to Overweight. The new note on the price target was released on April 23, 2024, representing the official price target for Heron Therapeutics Inc stock. Previously, the target price had yet another raise from $4 to $5, while Needham kept a Buy rating on HRTX stock.
The Average True Range (ATR) for Heron Therapeutics Inc is set at 0.19, with the Price to Sales ratio for HRTX stock in the period of the last 12 months amounting to 2.55.
How has HRTX stock performed recently?
Heron Therapeutics Inc [HRTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.42. With this latest performance, HRTX shares gained by 15.24% in over the last four-week period, additionally plugging by 39.08% over the last 6 months – not to mention a drop of -5.10% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for HRTX stock in for the last two-week period is set at 59.98, with the RSI for the last a single of trading hit 62.61, and the three-weeks RSI is set at 58.14 for Heron Therapeutics Inc [HRTX]. The present Moving Average for the last 50 days of trading for this stock 2.20, while it was recorded at 2.33 for the last single week of trading, and 1.92 for the last 200 days.
Heron Therapeutics Inc [HRTX]: Deeper insight into the fundamentals
Heron Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.29.
Insider trade positions for Heron Therapeutics Inc [HRTX]
The top three institutional holders of HRTX stocks are: RUBRIC CAPITAL MANAGEMENT LP with ownership of 26.71 million shares, which is approximately 17.5395%. VANGUARD GROUP INC, holding 8.62 million shares of the stock with an approximate value of $$30.16 million in HRTX stocks shares; and VANGUARD GROUP INC, currently with $$29.14 million in HRTX stock with ownership which is approximately 5.4663%.
